Therapeutic Outlook in DLBCL: Evaluating Treatment Sequencing from Front-line to Relapsed Refractory Disease - Episode 6
Second-line Treatment Landscape in Relapsed/Refractory DLBCL
A concise discussion of second-line treatment options for DLBCL, focusing on preferred regimens for transplant-eligible and ineligible patients, and tailored approaches based on relapse timing.
Video content above is prompted by the following:
Briefly discuss second-line (2L) treatment of DLBCL.
- What are preferred regimens for transplant ineligible versus transplant eligible?
- What are preferred regimens for patients that relapse within 12 months versus those that do not progress within 12 months?
Related Content:
